American Association for Cancer Research

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research

Webster K. Cavenee, Ph.D.  Eighth Annual Award Recipient
Webster K. Cavenee, Ph.D.
Director
Ludwig Institute for Cancer Research
La Jolla, Calif.


Dr. Cavenee will receive his award at the Opening Ceremony which will be held on Sunday, April 6, 2014, from 8 to 9 a.m. in the San Diego Convention Center. Visit the AACR Annual Meeting 2014 page for more information.

  • View the list of all prior recipients.

  • Learn more about the 2014 AACR award recipient.


The Award

The American Association for Cancer Research established this award in 2007 in honor of Margaret Foti, Ph.D., M.D. (h.c.), for her exemplary leadership of the AACR as its chief executive officer; for her sustained, outstanding work in fostering research, scholarly communications, education and training, science policy and public education; and for her extraordinary dedication and contributions to the conquest of cancer.

This award recognizes a true champion of cancer research, an individual who embodies the sustained commitment of Margaret Foti to the prevention and cure of cancer. The award is given to an individual whose leadership and extraordinary achievements in cancer research or in support of cancer research have made a major impact on the field. Such achievements include contributions to the acceleration of progress in cancer research, raising national or international awareness of cancer research, or other demonstrations of a sustained commitment to the conquest of cancer.

The Eighth Annual Award will be presented at the AACR Annual Meeting 2014, in San Diego, Calif., USA (April 5-9, 2014). The recipient must be present to receive the award unless otherwise unable to do so because of health restrictions or other serious conflicts.

The recipient will receive an honorarium of $10,000, a commemorative award, and support for the recipient and a guest to attend the AACR Annual Meeting.

Eligibility Criteria

  • Candidacy is open to all individuals who are affiliated with any organization whose mission supports cancer research or any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government.
  • Institutions or organizations are not eligible for the award.
  • Selection of the award recipient will be made on the basis of the candidate's sustained commitment to accelerating progress in cancer research. No regard will be given to race, gender, nationality, geographic location, or religious or political views.

Nomination Procedure

Nominations are closed.

Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves.

Selection

Candidates for the award will be considered by a prestigious committee of renowned international cancer leaders appointed by the president of the AACR. After careful deliberations by the committee, their recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision.

Selection of the award recipient will be made on the basis of the leadership and extraordinary achievements of the candidate. No regard will be given to race, gender, nationality, geographic location, or religious or political views.

Questions?

Linda Stokes, Program Associate
awards@aacr.org

American Association for Cancer Research
615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404

SPOTLIGHT

Webster K. Cavenee, Ph.D. Eighth Annual Award Recipient
Webster K. Cavenee, Ph.D.
Director
Ludwig Institute for Cancer Research
La Jolla, Calif.


Dr. Webster K. Cavenee, director of the Ludwig Institute for Cancer Research, San Diego, and distinguished professor at the University of California, San Diego, is being recognized for his pioneering work in cancer genetics, his leadership in the global fight against one of the most lethal cancers, glioblastoma multiforme, and his service to the AACR for more than 25 years.

Much of Dr. Cavenee’s career has been spent unraveling the inherited genetic changes that predispose individuals to cancer. His pioneering work in retinoblastoma provided the first indisputable genetic evidence for the existence of tumor suppressor genes in humans and confirmed the “two-hit” hypothesis, which had been proposed more than a decade earlier. He went on to identify other recessive genetic lesions that predispose individuals to Wilm’s tumor, osteosarcoma, and rhabdomyosarcoma, and established the concept of loss of heterozygosity, which is now known to contribute to multiple cancers, both spontaneous and hereditary.
 

Dr. Cavenee has also made key contributions to understanding of the biology of glioblastoma multiforme. His research in this area has helped illuminate the molecular mechanisms that drive the growth, migration, and survival of glioblastoma multiforme cells and identified potential new therapeutic approaches.

In addition to his extraordinary research accomplishments, Dr. Cavenee is an active leader in the global fight against glioblastoma multiforme. As a member of the Strategic Scientific Advisory Council of the Defeat GBM Research Collaborative he plays a key role in developing initiatives that aim to double the five-year survival rate for glioblastoma multiforme patients in just five years.
Dr. Cavenee was named among the inaugural class of Fellows of the AACR Academy in 2013. In addition, he has been recognized with numerous other awards throughout his career, including the AACR Princess Takamatsu Memorial Lectureship, the Albert Szent Gyorgyi Award from the National Foundation for Cancer Research, the Anthony Dipple Award from the European Association for Cancer Research, and the Farber Prize from the American Association of Neurological Surgeons. He is also an elected member of the National Academy of Science of the United States of America and the Institute of Medicine of the National Academies.
Dr. Cavenee received his undergraduate degree from Kansas State University in Manhattan, Kan., and his doctorate from the University of Kansas Medical School in Kansas City. After completing postdoctoral work at the Jackson Laboratory and the University of Utah, Cavenee held professorships at the University of Cincinnati in Ohio, and McGill University in Montreal, Quebec, Canada. He has been director of the Ludwig Institute for Cancer Research, San Diego, since 1991.